Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

SHANGHAI and HONG KONG, Aug. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration has approved a Phase II study of selinexor (XPOVIO®) for the treatment of patients with myelofibrosis (MF).

Final Results of a Phase 2 Clinical Trial of LCL161, An Oral SMAC Mimetic for Patients With Myelofibrosis

LCL161, a novel SMAC mimetic, demonstrates responses in patients with treatment-resistant myelofibrosis, including anemia responses.

Blood Advances
Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

Mutations in the calreticulin gene are seen in about 30% of essential thrombocythemia and primary myelofibrosis patients.


Functional Consequences of Mutations in Myeloproliferative Neoplasms

The most prevalent mutation, JAK2 V617F, is associated with the 3 entities polycythemia vera, essential thrombocythemia, and myelofibrosis, while CALR and MPL mutations are associated only with ET

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms

In myelofibrosis, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML. 

Frontiers in Immunology
FDA Grants Priority Review to Pacritinib for Myelofibrosis With Severe Thrombocytopenia

The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial

SAN MATEO, Calif., June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic. The study enrolled 195 patients based on a planned 180 patients across 21 countries. Topline data are anticipated in Q1 2022, and assuming positive results, the company intends to file a New Drug Application (NDA) with the US Food & Drug Administration (FDA) in H2 2022.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)